Shots:

• Intract to receive an up front- development & commercial milestone along with royalties on product sales. Bio-Thera gets global license to Intract’s Soteria & Phloral oral drug delivery platform to develop a mAb product for chronic GI inflammatory diseases
• Intract will be responsible for preclinical research of the product while Bio-Thera will get an option to expand the development of the product for multiple GI indications & will lead the manufacturing & commercialization of any approved products
• Intract’s Soteria protects proteins such as mAbs from degradation in intestinal lumen whereas Phloral utilizes pH & enzymes produced by colonic bacteria to allow payloads in the colon

  | Ref: Businesswire | Image: Businesswire